InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

9
Insider
Date
Role
Action
Shares
Price
Amount
Christopher Sarchi
1 Jun 2026
Chief Commercial Officer
Sold on a plan
12,000
$9.24
$110.88K
Christopher Sarchi
2 Apr 2026
Chief Commercial Officer
Sold on a plan
6,500
$8.01
$52.07K
Sushil Patel
2 Dec 2025
Chief Executive Officer
Sold on a plan
10,000
$11.13
$111.30K
Sushil Patel
16 Dec 2024
Chief Executive Officer
Sold on a plan
10,000
$12.42
$124.20K
Konstantinos Xynos
7 Jun 2024
Chief Medical Officer
Sold on a plan
15,881
$7.50
$119.11K
Sushil Patel
13 Jun 2023
Chief Strategy Officer
Sold on a plan
553
$23.44
$12.96K
Sushil Patel
13 Jun 2023
Chief Strategy Officer
Sold on a plan
5,145
$24.11
$124.05K
Tanya Lewis
13 Jun 2023
Chief Dev. Op. Officer
Sold on a plan
817
$23.45
$19.16K
Tanya Lewis
13 Jun 2023
Chief Dev. Op. Officer
Sold on a plan
12,043
$24.10
$290.24K
Showing 250 of 279 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 282
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 25
Sales on a Rule 10b5-1 plan 9
Sales straight out of an exercise 32
Sales at will 226
Transactions with no price 0
Shares from compensation/vesting 31,126,773
Sales filed before the plan box existed 186
History held since 25 Jul 2018